Lexology November 29, 2022
Reed Smith LLP

Life sciences collaborations often involve long-term complex commitments. For business development professionals and in-house lawyers, mitigating risk means striking a delicate balance at every phase of the life cycle.

At the contracting phase, parties must balance clarity with flexibility to allow for unknown future circumstances. At the operational phase, they should balance managing alliances with preserving rights. Finally, when a dispute arises, they must balance the competing objectives of enforcing rights and fostering a long-term productive partnership.

This briefing highlights steps business development professionals, alliance managers and in-house counsel can take at each stage of the life cycle of a typical life sciences transaction to reduce the frequency of these disputes and protect their employer’s position when such disputes do...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
Fierce Biotech Layoff Tracker 2024: BMS to cut 2K+ roles; Tessera trims workforce in shift to clinic
What Do Weight-Loss Drugs Mean for Diet Industry Built on Eating Less and Exercise?
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs

Share This Article